Embeddedness, social epistemology and breakthrough innovation: The case of the development of statins

Research Policy

Volumn 39, Issue 4, 2010, Pages 511-522

  Baba, Yasunori ^a   Walsh, John P ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Breakthrough innovation; National innovation system; Pharmaceutical industry; Scientific networks; Social capital

Indexed keywords

BREAKTHROUGH INNOVATIONS; NATIONAL INNOVATION SYSTEMS; PHARMACEUTICAL INDUSTRY; SCIENTIFIC NETWORKS; SOCIAL CAPITALS;

DRUG PRODUCTS PLANTS;

INNOVATION;

EID: 77950034067     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2010.01.016     Document Type: Article

References (57)

1. Anegawa T. Pharmaceutical Industry in Japan. In: Yoshimori M. (Ed). The Worldwide Pharmaceutical Industry (2007), University of Tokyo Press, Tokyo 211-282 (in Japanese)
2. Biddle J. Lessons from the Vioxx debacle: what the privatization of science can teach us about social epistemology. Social Epistemology 21 (2007) 21-39
3. Blume S.S. Cochlear implantation: establishing clinical feasibility 1957-1982. In: Rosenberg N., Gelijns A.C., and Dawkins H. (Eds). Sources of Medical Technology: Universities and Industry (1995), National Academy Press, Washington, DC 97-124
4. Brown M.S., and Goldstein J. A tribute to Akira Endo, discoverer of a 'penicillin' for cholesterol. Atherosclerosis 5 3 (2004) 13-16
5. Burt R.S. Structural Holes: The Social Structure of Competition (1992), Harvard University Press, Cambridge
6. In: Carlsson B. (Ed). Technological Systems and Economic Performance: The Case of Factory Automation (1995), Kluwer, Dordrecht
7. Cohen W.M., and Levinthal D.A. Absorptive capacity: a new perspective on learning and innovation. Administrative Science Quarterly 35 (1990) 128-152
8. Coleman J.S. Social capital in the creation of human capital. American Journal of Sociology Supplement 94 (1988) 95-120
9. Coleman J.S. Foundations of Social Theory (1990), Harvard University Press, Cambridge
10. In: Edquist C. (Ed). Systems of Innovation: Technologies, Institutions and Organizations (1997), Pinter, London
11. Endo A. The origin of statins. In: Matsuzawa Y., Kita T., et al. (Eds). Atherosclerosis XIII: Proceedings of the XIII International Symposium on Atherosclerosis (2004), Elsevier, Amsterdam 3-8
12. Endo A. A Gift from Nature: The Birth of the Biggest Blockbuster in the World (2006), Medical Review Publisher, Tokyo (in Japanese)
13. Endo A. The Discovery of Statin: Challenge Lowering Cholesterol (2006), Iwanami Shoten, Tokyo (in Japanese)
14. Feldman M., Gertler M., and Wolfe D. University technology transfer and national systems of innovation. Industry and Innovation 13 4 (2006) 359-370
15. Fleming L., and Sorenson O. Science as a map in technology search. Strategic Management Journal 25 8 and 9 (2004) 909-928
16. Freeman C. Technology Policy and Economic Performance: Lessons from Japan (1987), Pinter, London
17. Galambos L., and Swell J.E. Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and Mulford, 1895-1995 (1995), Cambridge University Press, Cambridge
18. Gambardella A. Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s (1995), Cambridge University Press, Cambridge
19. Goldstein, J., 2008. Award Presentation of Joseph Goldstein at Lasker-deBakey Clinical Medical Research Award, 2008. http://www.laskerfoundation.org/awards/2008_c_presentation.htm.
20. Goto A., and Odagiri H. Innovation in Japan (1997), Clarendon Press, Oxford
21. Granovetter M. The strength of weak ties. American Journal of Sociology 79 (1973) 1360-1380
22. Granovetter M. Economic action and social structure: the problem of embeddedness. American Journal of Sociology 91 (1985) 81-510
23. Grundy S. A letter from America to Dr. Endo. Atherosclerosis 5 3 (2004) 17-18
24. Hansen M.T. The search-transfer problem. Administrative Science Quarterly 44 (1999) 82-111
25. Hara T. Innovation in the Pharmaceutical Industry: the Process of Drug Discovery and Development (2003), Edward Elgar, Cheltham
26. Henderson R.M. The evolution of integrative capability: innovation in cardiovascular drug discovery. Industry and Corporate Change 3 3 (1994) 607-630
27. Henderson R.M., and Clark K.B. Architectural innovation: the reconfiguration of existing product technologies and the failure of established firms. Administrative Science Quarterly 35 (1990) 9-30
28. Henderson R., and Cockburn I. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal 15 (1994) 63-84
29. Loftus P. Pfizer's Lipitor patent reissue rejected. Wall Street Journal (2007) (16 August 2007)
30. In: Lundvall B. (Ed). National Systems of Innovation: Toward a Theory of Innovation and Interactive Learning (1992), Pinter, London
31. Macdonald J.S., Gerson R.J., Kornbrust D.J., et al. Preclinical evaluation of lovastin. American Journal of Cardiology 62 Supplement (1988) 16J-27J
32. Mehta J.N., and Khan L.A. Cardiology's 10 greatest discoveries of the 20th century. Texas Heart Institute Journal 29 3 (2002) 164-171
33. Metcalfe J.S., Andrew J., and Mina A. Emergent innovation systems and the delivery of clinical services: the case of intra-ocular lenses. Research Policy 34 (2005) 1283-1304
34. Murmann J.P. Knowledge and Competitive Advantage (2004), Cambridge University Press, Cambridge
35. Nakamura K. A unique cholesterol-lowering agent that no one had ever had before. Atherosclerosis 5 3 (2004) 19-20
36. Nelson R.R., and Winter S.G. In search of useful theory of innovation. Research Policy 5 (1977) 36-76
37. Nelson R.R. The role of knowledge in R&D efficiency. Quarterly Journal Economics 97 3 (1982) 453-470
38. In: Nelson R. (Ed). National Innovation Systems: A Comparative Analysis (1993), Oxford University Press, New York
39. NIH, 2006. The Stadtman way: a tale of two biochemists at NIH. (accessed 16th March 2009).
40. Nobel Prize Org., 2006. Michael S. Brown-biography. (accessed 12th January 2009).
41. Ono S. Ministry of Health, Labour and Welfare (MHLW) of Japan (2007), Wiley Encyclopedia of Clinical Trials pp. 1-8
42. Otsubo T. Research on development management: the case of Mevalotin. Oberlin Economics 42 (1999) 29-57 (in Japanese)
43. Pisano G. Science Business: The Promise, the Reality and the Future of Biotech (2006), Harvard Business School Press, Massachusetts
44. Putnam R.D. The prosperous community: social capital and public life. The American Prospect 13 (1993) 35-42
45. Ragin C.C. The Comparative Method (1987), University of California Press, Berkeley, CA
46. Rensberger B. Life Itself (1996), Cambridge University Press, Cambridge
47. Simon J. Pfizer's $10 billion pill. Fortune (2003) (6 January 2003)
48. Teece D.J., and Pisano G. Dynamic capabilities of firms. Industrial and Corporate Change 3 3 (1994) 537-556
49. Tushman M.L., and Anderson P. Technological discontinuities and organizational environments. Administrative Science Quarterly 31 3 (1986) 439-465
50. Uslaner, E.M., 2003. Trust in the knowledge society. Paper presented at the Conference on Social Capital, Cabinet of the Government of Japan, 24-25 March, 2003.
51. Uzzi B. The sources and consequences of embeddedness for the economic performance of organizations. American Sociological Review 61 (1996) 674-698
52. Vagelos R., and Galambos L. Medicine, Science and Merck (2004), Cambridge University Press, Cambridge
53. Vaughan D. The Challenger Launch Decision: Risky Technology, Culture, and Deviance at NASA (1996), University of Chicago Press, Chicago
54. Walsh J.P., Cohen W.M., and Cho C. Where excludability matters: material versus intellectual property in academic biomedical research. Research Policy 36 (2007) 1184-1203
55. Walsh V., and Le Roux M. Contingency in innovation and the role of national systems: taxol and taxotere in America and France. Research Policy 33 (2004) 1307-1327
56. Yamamoto A. Profile of Dr. Akira Endo. Atherosclerosis 5 3 (2004) 9
57. Yamamoto A. Three obstacles which confronted the development of compactin. Atherosclerosis 5 3 (2004) 21